A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Aug 2026 to Aug 10, 2026
    • Eligibility criteria expanded, about 9 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Start date changed from estimate of Jan 2026 to Jan 22, 2026
    • Site details revised at 8 of 8 sites
    v2
  3. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Trial Details
NCT Number NCT07321678
Lead Sponsor Ascletis Pharma (China) Co., Limited
Conditions
(from sponsor)		 T2DM (Type 2 Diabetes Mellitus)
Related terms Diabetes Mellitus, Type 2
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov